

Yoshiki Arakawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9396219/publications.pdf>

Version: 2024-02-01

169
papers

3,800
citations

117625

34
h-index

149698

56
g-index

173
all docs

173
docs citations

173
times ranked

5465
citing authors

#	ARTICLE	IF	CITATIONS
1	High intratumoral susceptibility signal grade on susceptibility-weighted imaging: a risk factor for hemorrhage after stereotactic biopsy. <i>Journal of Neurosurgery</i> , 2023, 138, 120-127.	1.6	5
2	The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. <i>Neuro-Oncology</i> , 2023, 25, 326-336.	1.2	23
3	The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. <i>Neuro-Oncology</i> , 2022, 24, 503-515.	1.2	31
4	Intraoperative Cerebrospinal Fluid Leak Graded by Esposito Grade Is a Predictor for Diabetes Insipidus After Endoscopic Endonasal Pituitary Adenoma Resection. <i>World Neurosurgery</i> , 2022, 158, e896-e902.	1.3	3
5	Intraoperative hand strength as an indicator of consciousness during awake craniotomy: a prospective, observational study. <i>Scientific Reports</i> , 2022, 12, 216.	3.3	3
6	Chrysanthemum morifolium Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis. <i>Cancers</i> , 2022, 14, 683.	3.7	1
7	Intra-cerebellar schwannoma with various degenerative changes: a case report and a systematic review. <i>BMC Neurology</i> , 2022, 22, 66.	1.8	1
8	Evaluation of the efficacy and safety of TASO313 in adults with recurrent glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2703-2715.	4.2	3
9	Optimal managements of elderly patients with glioblastoma. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 833-842.	1.3	2
10	Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2021, 23, 122-133.	1.2	102
11	So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?. <i>Neuro-Oncology</i> , 2021, 23, 295-303.	1.2	24
12	Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging—a controversy. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab086.	0.7	7
13	A descriptive analysis of end-of-life discussions for high-grade glioma patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 345-354.	1.6	1
14	Short diameter may be a useful simple indicator of the tumor response in skull base meningiomas after conventionally fractionated stereotactic radiotherapy. <i>European Radiology</i> , 2021, 31, 6367-6373.	4.5	0
15	Spinal cord astroblastoma with EWSR1-BEND2 fusion classified as HGNET-MN1 by methylation classification: a case report. <i>Brain Tumor Pathology</i> , 2021, 38, 283-289.	1.7	11
16	Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA. <i>Scientific Reports</i> , 2021, 11, 14408.	3.3	12
17	Factors associated with somnolence during brain function mapping in awake craniotomy. <i>Journal of Clinical Neuroscience</i> , 2021, 89, 349-353.	1.5	6
18	Determining the extent of tumor resection at surgical planning with 18F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1279-1292.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Effects of propofol on cortico-cortical evoked potentials in the dorsal language white matter pathway. <i>Clinical Neurophysiology</i> , 2021, 132, 1919-1926.	1.5	11
20	Assessment of neurocognitive function in association with WHO grades in gliomas. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106824.	1.4	5
21	Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. <i>BMC Cancer</i> , 2021, 21, 1025.	2.6	6
22	A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). <i>BMC Cancer</i> , 2021, 21, 1105.	2.6	6
23	Intracranial Growing Teratoma Syndrome With Intraventricular Lipid Accumulation. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e505-e507.	0.6	1
24	Brain MRI with Quantitative Susceptibility Mapping: Relationship to CT Attenuation Values. <i>Radiology</i> , 2020, 294, 600-609.	7.3	20
25	Effects of low-dose remifentanyl infusion on analgesic or antiemetic requirement during brain function mapping: A retrospective cohort study. <i>Acta Anaesthesiologica Scandinavica</i> , 2020, 64, 735-741.	1.6	6
26	Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. <i>Journal of Neuro-Oncology</i> , 2020, 148, 17-27.	2.9	5
27	Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 948-952.	1.3	6
28	Connectivity Gradient in the Human Left Inferior Frontal Gyrus: Intraoperative Cortico-Cortical Evoked Potential Study. <i>Cerebral Cortex</i> , 2020, 30, 4633-4650.	2.9	33
29	A Rare Case of Schwannoma Arising from the Dura Mater of the Petrosal Surface in the Posterior Cranial Fossa. <i>World Neurosurgery</i> , 2020, 141, 188-191.	1.3	1
30	Clinical characteristics, treatment, and survival outcome in pediatric patients with atypical teratoid/rhabdoid tumors: a retrospective study by the Japan Children's Cancer Group. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 25, 111-120.	1.3	16
31	Intraoperative Electrophysiologic Mapping of Medial Frontal Motor Areas and Functional Outcomes. <i>World Neurosurgery</i> , 2020, 138, e389-e404.	1.3	8
32	Hierarchical Cluster and Region of Interest Analyses Based on Mass Spectrometry Imaging of Human Brain Tumours. <i>Scientific Reports</i> , 2020, 10, 5757.	3.3	6
33	Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C. <i>Journal of Clinical Oncology</i> , 2020, 38, 2500-2500.	1.6	7
34	GCT-50. LONG-TERM OUTCOMES OF INTRACRANIAL GERMINOMA IN A SINGLE INSTITUTION. <i>Neuro-Oncology</i> , 2020, 22, iii338-iii338.	1.2	0
35	MBRS-22. SIGNIFICANCE OF <i>RNF213</i> IN TUMORGENICITY OF MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii402-iii402.	1.2	0
36	RONC-06. VOLUMETRIC-MODULATED ARC WHOLE-BRAIN RADIOTHERAPY FOR THE PREVENTION OF PERMANENT ALOPECIA IN PEDIATRIC PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, iii457-iii457.	1.2	0

#	ARTICLE	IF	CITATIONS
37	PATH-23. ADULT SPINAL CORD ASTROBLASTOMA WITH EWSR1-BEND2 FUSION. <i>Neuro-Oncology</i> , 2020, 22, iii429-iii429.	1.2	0
38	LGG-38. GENETIC ANALYSIS OF NEUROEPITHELIAL TUMORS IN THE PEDIATRIC AND ADOLESCENT AND YOUNG ADULT AGE IN A SINGLE INSTITUTE. <i>Neuro-Oncology</i> , 2020, 22, iii373-iii374.	1.2	0
39	EPID-17. A SINGLE INSTITUTE EXPERIENCE IN THE REGISTRATION STUDY OF PEDIATRIC SOLID TUMOR IN JAPAN CHILDREN'S CANCER GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii322-iii322.	1.2	0
40	THER-07. INHIBITION OF THE RAS SIGNALING ENHANCES VIRAL ONCOLYSIS IN MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii472-iii473.	1.2	0
41	Impact of Intraoperative 3-Tesla MRI on Endonasal Endoscopic Pituitary Adenoma Resection and a Proposed New Scoring System for Predicting the Utility of Intraoperative MRI. <i>Neurologia Medico-Chirurgica</i> , 2020, 60, 553-562.	2.2	3
42	COT-12 The role of clinical research professional in the registration study of pediatric solid tumor in Japan Children's Cancer Group. <i>Neuro-Oncology Advances</i> , 2020, 2, ii22-ii22.	0.7	0
43	COT-07 Cerebrovascular complications in adult patients with malignant brain tumor. <i>Neuro-Oncology Advances</i> , 2020, 2, ii21-ii22.	0.7	0
44	COT-13 Current situation and problems of cancer genomic profiling test in Kyoto University Hospital. <i>Neuro-Oncology Advances</i> , 2020, 2, ii22-ii22.	0.7	0
45	CTNI-66. ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. <i>Neuro-Oncology</i> , 2020, 22, ii57-ii58.	1.2	1
46	QOLP-07. HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH BEVACIZUMAB BEYOND PROGRESSION: A PROSPECTIVE TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii176-ii176.	1.2	0
47	ET-06 Suppression of glioblastoma through novel drug based on "Gene Switch Technology". <i>Neuro-Oncology Advances</i> , 2020, 2, ii6-ii6.	0.7	0
48	CTNI-22. RETROSPECTIVE ANALYSIS OF THE COMBINED TREATMENT OF VINCRIStINE, ACNU, CARBOPLATIN AND INTERFERON- γ PLUS RADIOTHERAPY (VAC-FERON-R) IN PATIENTS WITH DIFFUSE ASTROCYTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii47-ii47.	1.2	0
49	Intractable Medial Anastomotic Branches from the Lenticulostriate Artery Causing Recurrent Hemorrhages in Moyamoya Disease. <i>World Neurosurgery</i> , 2019, 127, 279-283.	1.3	11
50	Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor. <i>Cell Reports</i> , 2019, 26, 2608-2621.e6.	6.4	29
51	ATIM-07. EFFICACY AND SAFETY OF NIVOLUMAB IN PATIENTS WITH FIRST RECURRENCE OF GLIOBLASTOMA: A MULTICENTER, OPEN-LABEL, NON-COMPARATIVE STUDY (ONO-4538-19). <i>Neuro-Oncology</i> , 2019, 21, vi2-vi3.	1.2	1
52	ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS. <i>Neuro-Oncology</i> , 2019, 21, vi12-vi13.	1.2	0
53	PDTM-15. EMBRYONIC STEM CELL SIGNATURE DRIVES ATYPICAL TERATOID/RHABDOID TUMOR DEVELOPMENT IN HUMAN PLURIPOTENT STEM CELL-DERIVED TUMOR MODEL. <i>Neuro-Oncology</i> , 2019, 21, vi190-vi190.	1.2	0
54	COT-11 EFFECT OF PHYSICIAN SUPPORTS ON QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL BRAIN TUMOR RESEARCH. <i>Neuro-Oncology Advances</i> , 2019, 1, ii42-ii42.	0.7	0

#	ARTICLE	IF	CITATIONS
55	ACT-14 A FIRST-IN-HUMAN STUDY OF MUTANT IDH1 INHIBITOR DS-1001B IN PATIENTS WITH RECURRENT GLIOMAS. <i>Neuro-Oncology Advances</i> , 2019, 1, ii14-ii14.	0.7	0
56	TB-01 HUMAN IPS CELL-DERIVED BRAIN TUMOR MODEL UNCOVERS THE EMBRYONIC STEM CELL SIGNATURE AS A KEY DRIVER IN ATYPICAL TERATOID/RHABDOID TUMOR. <i>Neuro-Oncology Advances</i> , 2019, 1, ii10-ii10.	0.7	0
57	A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 348-359.	1.2	63
58	Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL). <i>Blood</i> , 2019, 134, 1586-1586.	1.4	4
59	Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2004-2004.	1.6	23
60	Addition of Amide Proton Transfer Imaging to FDG-PET/CT Improves Diagnostic Accuracy in Glioma Grading: A Preliminary Study Using the Continuous Net Reclassification Analysis. <i>American Journal of Neuroradiology</i> , 2018, 39, 265-272.	2.4	13
61	High-dose chemotherapy with autologous stem cell transplantation spares re-irradiation for recurrent intracranial germinoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27104.	1.5	8
62	JCOG0911 INTEGRA study: a randomized screening phase II trial of interferon- β plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 627-636.	2.9	49
63	Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation. <i>International Journal of Clinical Oncology</i> , 2018, 23, 608-614.	2.2	6
64	High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma. <i>Journal of Neurosurgery</i> , 2018, 128, 710-716.	1.6	36
65	CNS high-grade neuroepithelial tumor with BCOR internal tandem duplication: a comparison with its counterparts in the kidney and soft tissue. <i>Brain Pathology</i> , 2018, 28, 710-720.	4.1	67
66	CBMT-26. HIGH MOBILITY GROUP AT-HOOK 2 (HMGA2) IS A PROGNOSTIC FACTOR ASSOCIATED WITH MALIGNANT PHENOTYPE IN MEDULLOBLASTOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi38-vi38.	1.2	0
67	ATRT-28. RETROSPECTIVE ANALYSIS OF ATYPICAL TERATOID RHABDOID TUMOR IN THE ERA OF MULTIMODAL TREATMENT IN JAPAN. <i>Neuro-Oncology</i> , 2018, 20, i33-i34.	1.2	0
68	MBRS-40. HMGA2 IS A PROGNOSTIC FACTOR TO INDUCE MALIGNANT PHENOTYPE IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i137-i137.	1.2	0
69	Radiation-induced cystic brain necrosis developing 10 years after linac-based stereotactic radiosurgery for brain metastasis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy090.	0.4	3
70	Differential Diagnosis between Low-Grade and High-Grade Astrocytoma Using System A Amino Acid Transport PET Imaging with C-11-MeAIB: A Comparison Study with C-11-Methionine PET Imaging. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.8	8
71	PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. <i>PLoS ONE</i> , 2018, 13, e0194594.	2.5	19
72	Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3282-3289.	1.6	126

#	ARTICLE	IF	CITATIONS
73	Power Optimization for Chemical Exchange Saturation Transfer Imaging: A Phantom Study Using Egg White for Amide Proton Transfer Imaging Applications in the Human Brain. <i>Magnetic Resonance in Medical Sciences</i> , 2018, 17, 86-94.	2.0	9
74	Sudden spinal hemorrhage in a pediatric case with total body irradiation-induced cavernous hemangioma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27250.	1.5	5
75	Clinical impact of intraoperative CCEP monitoring in evaluating the dorsal language white matter pathway. <i>Human Brain Mapping</i> , 2017, 38, 1977-1991.	3.6	58
76	Whole brain radiotherapy with volumetric-modulated arc therapy for pediatric intracranial embryonic carcinoma prevents permanent alopecia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26434.	1.5	4
77	Diagnostic performance between contrast enhancement, proton MR spectroscopy, and amide proton transfer imaging in patients with brain tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 732-739.	3.4	28
78	RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6. <i>Developmental Cell</i> , 2017, 41, 315-329.e7.	7.0	26
79	Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 17-27.	2.2	8
80	Efficacy of Ifosfamide-Cisplatin-Etoposide (ICE) Chemotherapy for a CNS Germinoma in a Child With Down Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e39-e42.	0.6	5
81	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , 2017, 19, 12-21.	1.2	94
82	Quantitative assessment of gadolinium deposition in dentate nucleus using quantitative susceptibility mapping. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1352-1358.	3.4	31
83	LTK-03 MULTICENTER RANDOMIZED PLACEBO CONTROLLED TRIAL OF AUTOLOGOUS FORMALIN FIXED TUMOR VACCINE FOR NEWLY DIAGNOSED GLIOBLASTOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi315-vi315.	1.2	0
84	Differential diagnosis of posterior fossa brain tumors. <i>Medicine (United States)</i> , 2017, 96, e7767.	1.0	3
85	IMMU-24. PD-1/PD-L PATHWAY IS ASSOCIATED WITH TWO CELL PATTERN FORMATION IN INTRACRANIAL GERMINOMA. <i>Neuro-Oncology</i> , 2017, 19, vi117-vi117.	1.2	0
86	EXTH-50. DEVELOPMENT OF INVESTIGATOR INITIATED CLINICAL TRIAL OF TERT-TARGETING THERAPY USING ERIBULIN MESYLATE IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi83-vi83.	1.2	4
87	RTHP-30. EFFICACY AND SAFETY OF INTENSITY-MODULATED RADIOTHERAPY (IMRT) FOR WHOLE VENTRICLES IN PATIENTS WITH INTRACRANIAL GERMINOMA. <i>Neuro-Oncology</i> , 2017, 19, vi225-vi225.	1.2	0
88	Basic Techniques and Points to Notice in Glioma Surgery. <i>Japanese Journal of Neurosurgery</i> , 2017, 26, 650-656.	0.0	0
89	Diagnostic Performance and Safety of Positron Emission Tomography Using F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2017, 5, 10-21.	0.1	28
90	Lived experience in patients with recurrent glioblastoma in Japan: A narrative study. <i>Asian Pacific Island Nursing Journal</i> , 2017, 2, 157-165.	0.5	1

#	ARTICLE	IF	CITATIONS
91	Randomized, double-blind, phase III trial of a personalized peptide vaccination for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy.. Journal of Clinical Oncology, 2017, 35, 2000-2000.	1.6	0
92	GC-04INTENSITY-MODULATED RADIOTHERAPY (IMRT) FOR WHOLE VENTRICLES IN PATIENTS WITH INTRACRANIAL GERM CELL TUMOR. Neuro-Oncology, 2016, 18, iii42.4-iii43.	1.2	0
93	EPN-17AN ANALYSIS OF INTRACRANIAL EPENDYMOMAS FOR SURVIVAL AND PROGNOSTIC FACTORS. Neuro-Oncology, 2016, 18, iii34.1-iii34.	1.2	0
94	LG-76ANALYSIS OF PEDIATRIC CEREBELLAR GANGLIOGLIOMAS. Neuro-Oncology, 2016, 18, iii96.2-iii96.	1.2	0
95	ACTR-05. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP. Neuro-Oncology, 2016, 18, vi2-vi2.	1.2	1
96	Factors Predicting the Effects of Hybrid Assistive Limb Robot Suit during the Acute Phase of Central Nervous System Injury. Neurologia Medico-Chirurgica, 2016, 56, 33-37.	2.2	16
97	Visualization of heterogeneity and regional grading of gliomas by multiple features using magnetic resonance-based clustered images. Scientific Reports, 2016, 6, 30344.	3.3	14
98	Effectiveness of neuroendoscopic ventricular irrigation for ventriculitis. Clinical Neurology and Neurosurgery, 2016, 146, 147-151.	1.4	17
99	Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma. International Journal of Clinical Oncology, 2016, 21, 1023-1029.	2.2	8
100	T1-weighted MR imaging of glioma at 3T: a comparative study of 3D MPRAGE vs. conventional 2D spin-echo imaging. Clinical Imaging, 2016, 40, 1257-1261.	1.5	9
101	Clinicopathological, Radiological, and Genetic Analyses of Cerebellar Gangliogliomas with Long-Term Survival. World Neurosurgery, 2016, 94, 521-528.	1.3	3
102	A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neuro-Oncology Practice, 2016, 3, 272-280.	1.6	34
103	Temporal bone chondroblastoma totally invisible on MRI. Auris Nasus Larynx, 2016, 43, 468-471.	1.2	7
104	JCOG0504: A phase III randomized trial of surgery with whole brain radiation therapy versus surgery with salvage stereotactic radiosurgery in patients with 1 to 4 brain metastases.. Journal of Clinical Oncology, 2016, 34, 2003-2003.	1.6	9
105	Long-term Outcomes of Conventionally-fractionated High-precision Radiotherapy for Craniopharyngioma. Japanese Journal of Neurosurgery, 2016, 25, 646-653.	0.0	1
106	Surgical Management of Recurrent Spontaneous Spinal Epidural Hematoma With 3 Episodes. Spine, 2015, 40, E996-E998.	2.0	11
107	Grading Meningioma. Medicine (United States), 2015, 94, e549.	1.0	17
108	Z-Spectrum Analysis Provides Proton Environment Data (ZAPPED): A New Two-Pool Technique for Human Gray and White Matter. PLoS ONE, 2015, 10, e0119915.	2.5	2

#	ARTICLE	IF	CITATIONS
109	ATCT-03 RETROSPECTIVE REVIEW OF GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB-CONTAINING AND NON-BEVACIZUMAB-CONTAINING REGIMENS IN A SINGLE INSTITUTION. <i>Neuro-Oncology</i> , 2015, 17, v1.3-v1.	1.2	0
110	ATCT-23 MULTICENTER RETROSPECTIVE STUDY TO COMPARE CHEMORADIOTHERAPY WITH TEMOZOLOMIDE OR ACNU IN 535 ANAPLASTIC GLIOMAS. <i>Neuro-Oncology</i> , 2015, 17, v6.3-v6.	1.2	0
111	Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography. <i>Clinical Imaging</i> , 2015, 39, 390-395.	1.5	30
112	Grading glial tumors with amide proton transfer MR imaging: different analytical approaches. <i>Journal of Neuro-Oncology</i> , 2015, 122, 339-348.	2.9	75
113	Apparent Diffusion Coefficient and Transient Neurological Deficit after Revascularization Surgery in Moyamoya Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 2054-2059.	1.6	9
114	A possible variant of negative motor seizure arising from the supplementary negative motor area. <i>Clinical Neurology and Neurosurgery</i> , 2015, 134, 126-129.	1.4	4
115	Estimation of proliferative potential of central neurocytoma: correlational analysis of minimum ADC and maximum SUV with MIB-1 labeling index. <i>Acta Radiologica</i> , 2015, 56, 114-120.	1.1	6
116	Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI. <i>Clinical Radiology</i> , 2015, 70, 1393-1399.	1.1	32
117	Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma. <i>Pediatrics International</i> , 2015, 57, 169-171.	0.5	8
118	Primary central nervous system lymphoma: is absence of intratumoral hemorrhage a characteristic finding on MRI?. <i>Radiology and Oncology</i> , 2015, 49, 128-134.	1.7	12
119	High mobility group A1 expression shows negative correlation with recurrence time in patients with glioblastoma multiforme. <i>Pathology Research and Practice</i> , 2015, 211, 596-600.	2.3	9
120	Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region. <i>BMC Cancer</i> , 2014, 14, 641.	2.6	20
121	Intraoperative dorsal language network mapping by using single-pulse electrical stimulation. <i>Human Brain Mapping</i> , 2014, 35, 4345-4361.	3.6	120
122	Pineal parenchymal tumor of intermediate differentiation: Treatment outcomes of five cases. <i>Molecular and Clinical Oncology</i> , 2014, 2, 197-202.	1.0	31
123	Dysembryoplastic neuroepithelial tumor with rapid recurrence of pilocytic astrocytoma component. <i>Brain Tumor Pathology</i> , 2014, 31, 144-148.	1.7	4
124	Quantitative imaging values of CT, MR, and FDG-PET to differentiate pineal parenchymal tumors and germinomas: are they useful?. <i>Neuroradiology</i> , 2014, 56, 297-303.	2.2	36
125	Voxel-based clustered imaging by multiparameter diffusion tensor images for glioma grading. <i>NeuroImage: Clinical</i> , 2014, 5, 396-407.	2.7	45
126	Usefulness of Tumor Blood Flow Imaging by Intraoperative Indocyanine Green Videoangiography in Hemangioblastoma Surgery. <i>World Neurosurgery</i> , 2014, 82, e495-e501.	1.3	44

#	ARTICLE	IF	CITATIONS
127	Differential Gene Expression in Relation to the Clinical Characteristics of Human Brain Arteriovenous Malformations. <i>Neurologia Medico-Chirurgica</i> , 2014, 54, 163-175.	2.2	22
128	Treatment for Infection of Artificial Dura Mater Using Free Fascia Lata. <i>Journal of Craniofacial Surgery</i> , 2014, 25, 1252-1255.	0.7	14
129	Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. <i>Radiation Oncology</i> , 2013, 8, 97.	2.7	45
130	Efficacy of salvage stereotactic radiotherapy for recurrent glioma: impact of tumor morphology and method of target delineation on local control. <i>Cancer Medicine</i> , 2013, 2, 942-949.	2.8	10
131	Organizing Intracerebral Hematoma Mimicking a Recurrent Brain Tumor on FDG-PET. <i>Clinical Nuclear Medicine</i> , 2013, 38, e411-e413.	1.3	3
132	Retrospective Analysis of Bevacizumab in Combination With Ifosfamide, Carboplatin, and Etoposide in Patients With Second Recurrence of Glioblastoma. <i>Neurologia Medico-Chirurgica</i> , 2013, 53, 779-785.	2.2	10
133	In vivo fluorescence resonance energy transfer imaging reveals differential activation of Rho-family GTPases in glioblastoma cell invasion. <i>Journal of Cell Science</i> , 2012, 125, 858-868.	2.0	116
134	Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. <i>Journal of Neuro-Oncology</i> , 2012, 109, 425-432.	2.9	42
135	Hypofractionated stereotactic radiotherapy for acoustic neuromas: safety and effectiveness over 8 years of experience. <i>International Journal of Clinical Oncology</i> , 2011, 16, 27-32.	2.2	17
136	F11-Mediated Inhibition of RhoA Signalling Enhances the Spread of Vaccinia Virus In Vitro and In Vivo in an Intranasal Mouse Model of Infection. <i>PLoS ONE</i> , 2009, 4, e8506.	2.5	53
137	Endogenous tenascin ϵ C enhances glioblastoma invasion with reactive change of surrounding brain tissue. <i>Cancer Science</i> , 2009, 100, 1451-1459.	3.9	53
138	Angioplasty and stent deployment in acute sinus thrombosis following endovascular treatment of dural arteriovenous fistulae. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 725-727.	1.5	12
139	Long term outcomes in patients with intracranial germinomas: a single institution experience of irradiation with or without chemotherapy. <i>Journal of Neuro-Oncology</i> , 2008, 88, 161-167.	2.9	47
140	Plical resection in pre-temporal approach for basilar bifurcation aneurysms: preliminary surgical experience and cadaveric study. <i>Acta Neurochirurgica</i> , 2008, 150, 749-756.	1.7	4
141	Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell ϵ derived neural precursors. <i>Journal of Neuroscience Research</i> , 2008, 86, 270-280.	2.9	142
142	ADVANCED MAGNETIC RESONANCE IMAGING OF CEREBRAL CAVERNOUS MALFORMATIONS. <i>Neurosurgery</i> , 2008, 63, 790-798.	1.1	46
143	ADVANCED MAGNETIC RESONANCE IMAGING OF CEREBRAL CAVERNOUS MALFORMATIONS. <i>Neurosurgery</i> , 2008, 63, 782-789.	1.1	30
144	The Release of Vaccinia Virus from Infected Cells Requires RhoA-mediated Modulation of Cortical Actin. <i>Cell Host and Microbe</i> , 2007, 1, 227-240.	11.0	81

#	ARTICLE	IF	CITATIONS
145	F11L-Mediated Inhibition of RhoA-mDia Signaling Stimulates Microtubule Dynamics during Vaccinia Virus Infection. <i>Cell Host and Microbe</i> , 2007, 1, 213-226.	11.0	63
146	Administration of Ex Vivo-expanded Bone Marrow-derived Endothelial Progenitor Cells Attenuates Focal Cerebral Ischemia-reperfusion Injury in Rats. <i>Neurosurgery</i> , 2006, 59, 679-686.	1.1	57
147	Absence epilepsy associated with moyamoya disease. <i>Journal of Neurosurgery: Pediatrics</i> , 2006, 104, 265-268.	1.3	6
148	Microfiberscope Coaxial Technique in Neuroendoscopic Surgery. <i>Minimally Invasive Neurosurgery</i> , 2006, 49, 380-383.	0.9	1
149	Molecular Identification and Characterization of a Family of Kinases with Homology to Ca ²⁺ /Calmodulin-dependent Protein Kinases I/IV. <i>Journal of Biological Chemistry</i> , 2006, 281, 20427-20439.	3.4	45
150	The Rho-mDia1 Pathway Regulates Cell Polarity and Focal Adhesion Turnover in Migrating Cells through Mobilizing Apc and c-Src. <i>Molecular and Cellular Biology</i> , 2006, 26, 6844-6858.	2.3	171
151	Application of the Bipolar Forceps with Heat Pipe Technology (IsoCool™) in Neurosurgery. <i>Japanese Journal of Neurosurgery</i> , 2005, 14, 698-705.	0.0	3
152	Long-term outcome in patients harboring intracranial ependymoma. <i>Journal of Neurosurgery</i> , 2005, 103, 31-37.	1.6	65
153	Quantitative analysis of topoisomerase III α to rapidly evaluate cell proliferation in brain tumors. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 971-976.	2.1	8
154	Overexpression of RFT induces G1 α S arrest and apoptosis via p53/p21Waf1 pathway in glioma cell. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 902-908.	2.1	8
155	Milrinone Reduces Cerebral Vasospasm After Subarachnoid Hemorrhage of WFNS Grade IV or V. <i>Neurologia Medico-Chirurgica</i> , 2004, 44, 393-401.	2.2	33
156	Molecular Cloning and Characterization of CLICK-III/CaMKII β , a Novel Membrane-anchored Neuronal Ca ²⁺ /Calmodulin-dependent Protein Kinase (CaMK). <i>Journal of Biological Chemistry</i> , 2003, 278, 18597-18605.	3.4	50
157	Control of axon elongation via an SDF-1 α /Rho/mDia pathway in cultured cerebellar granule neurons. <i>Journal of Cell Biology</i> , 2003, 161, 381-391.	5.2	177
158	Growth Hormone-Secreting Pituitary Adenoma Associated With Primary Moyamoya Disease-Case Report-. <i>Neurologia Medico-Chirurgica</i> , 2003, 43, 356-359.	2.2	9
159	ROCK and mDia1 antagonize in Rho-dependent Rac activation in Swiss 3T3 fibroblasts. <i>Journal of Cell Biology</i> , 2002, 157, 819-830.	5.2	193
160	Multiple spatiotemporal modes of actin reorganization by NMDA receptors and voltage-gated Ca ²⁺ channels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14458-14463.	7.1	83
161	A papillary glioneuronal tumor arising in an elderly woman: a case report. <i>Brain Tumor Pathology</i> , 2002, 19, 35-39.	1.7	41
162	Milrinone for the Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage: Report of Seven Cases. <i>Neurosurgery</i> , 2001, 48, 723-730.	1.1	103

#	ARTICLE	IF	CITATIONS
163	Milrinone for the Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage: Report of Seven Cases. <i>Neurosurgery</i> , 2001, 48, 723-730.	1.1	85
164	Terson Syndrome Caused by Ventricular Hemorrhage Associated With Moyamoya Disease. Case Report.. <i>Neurologia Medico-Chirurgica</i> , 2000, 40, 480-483.	2.2	7
165	A Case of Epidermoid with Malignant Component. <i>Japanese Journal of Neurosurgery</i> , 2000, 9, 120-124.	0.0	0
166	The brain finger protein gene (ZNF179), a member of the RING finger family, maps within the Smith-Magenis syndrome region at 17p11.2. <i>American Journal of Medical Genetics Part A</i> , 1997, 69, 320-324.	2.4	14
167	The brain finger protein gene (ZNF179), a member of the RING finger family, maps within the Smith-Magenis syndrome region at 17p11.2. <i>American Journal of Medical Genetics Part A</i> , 1997, 69, 320-324.	2.4	1
168	Frequent deletions of material from chromosome arm 1p in oligodendroglial tumors revealed by double-target fluorescence in situ hybridization and microsatellite analysis. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 295-300.	2.8	35
169	Whole-genome sequencing analysis of an atypical teratoid/rhabdoid tumor in a patient with Phelan-McDermid syndrome: a case report and systematic review. <i>Brain Tumor Pathology</i> , 0, , .	1.7	2